Abstract

Objectives: To describe a protocol-driven layered bio-stimulation strategy in mid-face rejuvenation and to demonstrate how anatomical depth control and structured sequencing can improve predictability, safety, and clinical reproducibility in injectable treatments. Introduction: Mid-face rejuvenation remains complex due to anatomical variability and inconsistent tissue response to bio-stimulatory injectables. Product-centered approaches alone may lead to unpredictable structural and dermal outcomes. A structured protocol emphasizing depth control and treatment sequencing may enhance clinical consistency. Materials / method: A retrospective analysis of 72 consecutive patients treated between 2023–2025 was performed. The protocol incorporated deep structural collagen induction, intermediate dermal modulation, and superficial vascular support. Injection planes were determined according to anatomical mapping principles. Clinical outcomes were assessed using GAIS scoring, standardized photography, and ultrasound-based dermal thickness measurement at 12 weeks. Results: Improved structural support and dermal homogeneity were observed in the majority of patients. Mean dermal thickness increased by 16–18% at 12 weeks. Patient satisfaction reached 88%. No major vascular complications or persistent nodular formations were reported. Conclusion: A protocol-driven layered injectable approach based on anatomical sequencing may enhance safety and reproducibility in mid-face bio-stimulation. Structured depth control appears to improve clinical predictability compared to non-sequenced injectable treatments.